TACE plus immune checkpoint inhibitor-based systemic therapies for hepatocellular carcinoma
Ce dossier présente 2 essais randomisés multicentriques de phase III évaluant, chez des patients atteints d'un carcinome hépatocellulaire non résécable, l'intérêt d'ajouter à une chimioembolisation transartérielle hépatique un traitement par lenvatinib-pembrolizumab ou un traitement par durvalumab-bévacizumab
The advent of immunotherapy based on immune checkpoint inhibitors has improved the treatment of advanced hepatocellular carcinoma and is now the firstline standard of care for systemic therapy.1 In light of this progress, the introduction of immune checkpoint inhibitor-based therapy combinations for the treatment of earlier stages of disease seems a reasonable step. In this context, the results reported in The Lancet from Bruno Sangro and colleagues2 for the EMERALD-1 study, and Masatoshi Kudo and colleagues3 for the LEAP-012 study are of great interest, both investigating the combination of transarterial chemoembolisation (TACE) plus anti-PD-L1 or PD-1 and anti-VEGF or multikinase inhibitor therapy.
The Lancet , commentaire, 2024